Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1896 1
1953 1
1955 2
1957 1
1962 2
1966 1
1967 1
1970 1
1974 1
1975 5
1977 3
1978 4
1979 1
1980 3
1981 2
1982 1
1983 6
1984 3
1985 6
1986 7
1987 7
1988 8
1989 9
1990 10
1991 11
1992 7
1993 14
1994 15
1995 12
1996 15
1997 18
1998 34
1999 33
2000 40
2001 50
2002 39
2003 39
2004 53
2005 53
2006 54
2007 60
2008 68
2009 84
2010 99
2011 117
2012 117
2013 102
2014 176
2015 189
2016 192
2017 217
2018 329
2019 346
2020 389
2021 504
2022 558
2023 555
2024 227

Text availability

Article attribute

Article type

Publication date

Search Results

4,326 results

Results by year

Filters applied: . Clear all
The following term was ignored: %
The following term was not found in PubMed: 20Habermann
Page 1
Future Projections in Thyroid Eye Disease.
Barbesino G, Salvi M, Freitag SK. Barbesino G, et al. J Clin Endocrinol Metab. 2022 Aug 8;107(Suppl_1):S47-S56. doi: 10.1210/clinem/dgac252. J Clin Endocrinol Metab. 2022. PMID: 36346684 Free PMC article. Review.
Nonsteroidal oral immunosuppressive agents offer modest benefit in TED. Several immunomodulatory monoclonal antibodies, including rituximab and tocilizumab, have shown efficacy for inactivating TED. ...CONCLUSION: New, albeit incomplete, understanding of the molecul …
Nonsteroidal oral immunosuppressive agents offer modest benefit in TED. Several immunomodulatory monoclonal antibodies, including rit …
Teprotumumab: A Review in Thyroid Eye Disease.
Nie T, Lamb YN. Nie T, et al. Drugs. 2022 Nov;82(17):1663-1670. doi: 10.1007/s40265-022-01804-1. Epub 2022 Nov 23. Drugs. 2022. PMID: 36418673 Free PMC article. Review.
Early real-world experience suggests teprotumumab may also be beneficial in a more diverse TED population. Teprotumumab is the first approved treatment for TED and is effective at reducing symptoms which are often unamenable to historical pharmacological interventio …
Early real-world experience suggests teprotumumab may also be beneficial in a more diverse TED population. Teprotumumab is the first …
It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
Girnita L, Smith TJ, Janssen JAMJL. Girnita L, et al. J Clin Endocrinol Metab. 2022 Aug 8;107(Suppl_1):S1-S12. doi: 10.1210/clinem/dgac045. J Clin Endocrinol Metab. 2022. PMID: 35167695 Free PMC article.
CONTEXT: Thyroid eye disease (TED) is a complex autoimmune disease process. Orbital fibroblasts represent the central orbital immune target. Involvement of the TSH receptor (TSHR) in TED is not fully understood. IGF-I receptor (IGF-IR) is overexpressed in several ce …
CONTEXT: Thyroid eye disease (TED) is a complex autoimmune disease process. Orbital fibroblasts represent the central orbital immune …
Dysthyroid Optic Neuropathy.
Agarwal A, Khanam S. Agarwal A, et al. 2022 Oct 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2022 Oct 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 33231969 Free Books & Documents.
The European Group on Grave's Orbitopathy (EUGOGO) classifies the severity of TED as mild, moderate-severe, or sight-threatening. Sight threatening TED, characterized by DON and/or keratopathy, warrants the need for urgent intervention. DON is a multifactorial entit …
The European Group on Grave's Orbitopathy (EUGOGO) classifies the severity of TED as mild, moderate-severe, or sight-threatening. Sig …
Eyelid Surgery in Thyroid Eye Disease.
Naik MN, Walvekar P, Vasanthapuram VH, Shankar L. Naik MN, et al. Ophthalmic Plast Reconstr Surg. 2023 Dec 1;39(6S):S92-S104. doi: 10.1097/IOP.0000000000002543. Epub 2023 Dec 4. Ophthalmic Plast Reconstr Surg. 2023. PMID: 38054989 Review.
PURPOSE: To review and summarize a comprehensive synopsis of surgery of the eyelid in thyroid eye disease (TED). METHODS: A PubMed search for specific eyelid manifestations of TED was performed. ...Entropion and Epiblepharon are rare in TED, and may resolve s …
PURPOSE: To review and summarize a comprehensive synopsis of surgery of the eyelid in thyroid eye disease (TED). METHODS: A PubMed se …
Thyroid Eye Disease.
Shah SS, Patel BC. Shah SS, et al. 2023 May 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 May 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 35881739 Free Books & Documents.
Thyroid eye disease (TED) is a chronic immune-mediated inflammation of the orbit. It is the most common cause of unilateral and bilateral proptosis in adults. ...The definition and understanding of TED have evolved over the years....
Thyroid eye disease (TED) is a chronic immune-mediated inflammation of the orbit. It is the most common cause of unilateral and bilat …
Phenotypes of Thyroid Eye Disease.
Uddin JM, Rubinstein T, Hamed-Azzam S. Uddin JM, et al. Ophthalmic Plast Reconstr Surg. 2018 Jul/Aug;34(4S Suppl 1):S28-S33. doi: 10.1097/IOP.0000000000001147. Ophthalmic Plast Reconstr Surg. 2018. PMID: 29905636 Review.
PURPOSE: To describe a new classification system of thyroid eye disease (TED) based on the phenotypic features (clinical and radiologic) of the disease. ...CONCLUSIONS: The observable characteristics of TED are determined by the underlying pathophysiology of the dis …
PURPOSE: To describe a new classification system of thyroid eye disease (TED) based on the phenotypic features (clinical and radiolog …
Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
Kossler AL, Douglas R, Dosiou C. Kossler AL, et al. J Clin Endocrinol Metab. 2022 Aug 8;107(Suppl_1):S36-S46. doi: 10.1210/clinem/dgac168. J Clin Endocrinol Metab. 2022. PMID: 36346685 Free PMC article. Review.
RESULTS: Randomized clinical trials demonstrating the efficacy of teprotumumab for TED led to Food and Drug Administration approval. Teprotumumab is gradually replacing immunosuppressive agents as first-line therapy in the United States for active moderate-to-severe TED …
RESULTS: Randomized clinical trials demonstrating the efficacy of teprotumumab for TED led to Food and Drug Administration approval. …
How patients experience thyroid eye disease.
Smith TJ, Hegedüs L, Lesser I, Perros P, Dorris K, Kinrade M, Troy-Ott P, Wuerth L, Nori M. Smith TJ, et al. Front Endocrinol (Lausanne). 2023 Nov 9;14:1283374. doi: 10.3389/fendo.2023.1283374. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38027128 Free PMC article.
OBJECTIVE: To determine the impact of thyroid eye disease (TED) on patients in various stages of the disease. BACKGROUND: TED is a debilitating and potentially sight-threatening inflammatory autoimmune disease that is frequently misdiagnosed. ...RESULTS: The 443 res …
OBJECTIVE: To determine the impact of thyroid eye disease (TED) on patients in various stages of the disease. BACKGROUND: TED …
Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease.
Subramanian PS, Cho RI, Kahana A. Subramanian PS, et al. Curr Opin Ophthalmol. 2023 Nov 1;34(6):487-492. doi: 10.1097/ICU.0000000000000997. Epub 2023 Aug 23. Curr Opin Ophthalmol. 2023. PMID: 37610428 Review.
PURPOSE OF REVIEW: Teprotumumab, an inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), was approved by the US Food and Drug Administration in January 2020 for the treatment of thyroid eye disease (TED). The clinical trials leading to its approval enrolled pat …
PURPOSE OF REVIEW: Teprotumumab, an inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), was approved by the US Food and Drug Ad …
4,326 results